| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INBS | Common Stock | Exercise of in-the-money or at-the-money derivative security | +9.39K | +95.99% | 19.2K | Mar 20, 2024 | Held by Anest Holdings Pty Ltd | F1, F2, F4 | ||
| holding | INBS | Common Stock | 314 | Mar 20, 2024 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INBS | Common Stock Warrants (Series F) | Exercise of in-the-money or at-the-money derivative security | $0 | -9.39K | -100% | $0.00* | 0 | Mar 20, 2024 | Common Stock | 9.39K | Held by Anest Holdings Pty Ltd | F1, F2, F3, F4 |
| Id | Content |
|---|---|
| F1 | The number of reported securities has been adjusted in order to reflect a 1-for-12 reverse stock split effected on January 26, 2024 (the "Reverse Stock Split"). |
| F2 | The Series F Warrants have an exercise price is $6.60 per share (after Reverse Stock Split related adjustments) and are also exercisable pursuant to an alternate cashless exercise formula set forth in the warrant. The Series F Warrants in the reported transaction were exercised pursuant to the alternate cashless exercise formula for an equal number of shares of common stock on a one-for-one basis, without payment of additional consideration therefore. |
| F3 | The Series F Warrants became exercisable on November 17, 2023, the date the Issuer's stockholders approved, for purposes of complying with Nasdaq Listing Rules 5635(c) and (d), the issuance of the shares underlying the Series F Warrants. |
| F4 | These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director. |